Evaluating the Effects of Electroacupuncture and Rosiglitazone Combined Therapy
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
Aims: To evaluate the efficacy of rosiglitazone (TZD) and electroacupuncture (EA) combined
therapy on patients with type 2 diabetes mellitus (T2DM). A randomized single-blind placebo
controlled clinical trial was used.
Methods: A total of 31 newly diagnostic type 2 diabetic patients, who fulfilled the
eligibility criteria were recruited and received various allocated interventions. They were
randomly assigned into two groups, the control group (TZD, N=15) and the experimental group
(TZD + EA, N=16). Changes in their plasma free fatty acid (FFA), glucose and insulin levels
together with their homeostasis model assessment (HOMA) indices were statistically assessed
between before and after treatment. Hypoglycemic activity (%) was also compared between these
two groups.
Expecting Results: This study will compare the hypoglycemic activity and the ability of
improving insulin resistance between the TZD and TZD+EA group. Also, the lowering effect of
the plasma FFA concentration will be investigated.